New hope for rare sarcomas: targeted pill attacks Cancer's DNA repair

NCT ID NCT05515575

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called niraparib in people with advanced soft tissue sarcoma that has certain DNA repair gene changes. The goal is to see if the drug can stop or slow tumor growth. About 8 adults with inoperable or metastatic sarcoma will take niraparib pills and be monitored for side effects and how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA UTERUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma uterine corpus sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA UTERUS SARCOMA,SOFT TISSUE

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.